Senores Pharmaceuticals Ltd (SENORES) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company delivered a strong performance across all segments in Q2 FY26, with consolidated revenue growing 61% YoY, driven primarily by new product launches in regulated markets.
- Profitability saw a significant improvement, with EBITDA growing 113% YoY and PAT increasing by 131% YoY, reflecting an enhanced product mix with a higher share of own-product launches.
- The company is undergoing a structural advancement, focusing on backward integration with its API facilities and forward integration through its new US-based entity, Zoraya Pharmaceuticals, to strengthen its market presence.
- Operating cash flow generation was robust at approximately INR 27 crores in H1 FY26, a more than threefold increase from H1 FY25, indicating improved capital efficiency despite strong business growth.
- The company remains confident in its annual guidance, reiterating its target of at least 50% growth in top-line and 100% growth in PAT for FY26 over FY25.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.